Coming FDA’s Public Hearing Will Not Focus On CBD Regulation But Instead Discuss Different Effects On Genders And Pregnancy
Last month, the U.S. Food and Drug Administration (FDA) announced that it would hold the public meeting on cannabidiol (CBD) and other cannabinoids to discuss the differing way these ingredients effects each gender. However, this might not lead to the resolution of regulation of ingestible CBD products as many had anticipated. This conference titled, “CBD and Other Cannabinoids: Sex and Gender Difference in Use and Responses” will discuss the uses of CBD and other cannabinoids in pregnancy, sex differences in the effects of CBD and other cannabinoids, and perspective of the government agency on CBD research. This event might give us a peek into the future regulations of CBD ingestible products.
It sounds to me like this is a listening session for researchers, educators, clinicians and patients to talk to FDA about the studies they’ve undertaken, the data they’ve reviewed, the patients they’ve treated, their personal experience, and the like.
The agency is trying to look at CBD’s effect on gender since a lot of the time CBD is marketed for anxiety, depression, chronic pain, and sleep disturbances. Most of these conditions are seen more in women than men. The fact that the FDA is looking into this suggests that they consider some of these as medical conditions and the conference will focus mostly on drug products rather than dietary supplements. Since this conference will be highly data-driven, there is a little chance for us to understand the FDA’s thinking on this subject.
Read Full Article: https://www.cspdailynews.com
CBD is one of many powerful cannabinoids found in hemp known for helping to support our body and mind. Here at Healing Dragon CBD we do not intend to make unfounded medical claims about the health benefits of CBD. The FDA has not confirmed that CBD cures, treats, or prevents any diseases or conditions. Please take a moment to read our full disclosure statement.